Seeing Clearly: Emerging Treatments for Vision Problems
Vision problems have become a common issue for many people worldwide. With the advancements in technology, more and more people have become glued to their screens, leading to an increase in eye strain and other vision problems. Over time, traditional treatments such as glasses, contact lenses, and surgical procedures have been utilized. However, in recent years, several emerging treatments have shown a promising rate of success in treating vision problems. In this article, we’ll discuss the latest emerging treatments such as RGN-259, Visomitin, A5, A7, A11 Bioregulator Peptides, Can C eye drops, Red Light Therapy, Normoftol, BPC 157 and their ability to restore vision.
RGN-259:
RGN-259, a topical eye drop, has shown promising results in treating dry eye syndrome, a condition where the eye fails to produce enough tears, leading to dryness and inflammation. Clinical studies have revealed that after just two weeks of treatment, the drop can significantly reduce dry eye symptoms and improve overall eye health.
RGN-259 is a sterile and preservative-free eye drop that contains Thymosin beta 4 (Tβ4) as its active ingredient[2]. It has been developed by RegeneRx Biopharmaceuticals for the treatment of various ocular diseases, including dry eye syndrome and neurotrophic keratopathy[2][3].
**Mechanism of Action**
RGN-259 works by promoting the healing of persistent epithelial defects in the cornea[1]. Tβ4, the active ingredient in RGN-259, has anti-inflammatory and wound-healing properties[3]. It has been shown to improve corneal integrity, reduce inflammation, and promote recovery of mucins and goblet cells in a dry eye mouse model[5].
**Applications**
RGN-259 has been studied for the treatment of dry eye syndrome and neurotrophic keratopathy[1][2][3]. In a Phase 2 clinical trial for dry eye syndrome, RGN-259 was found to improve ocular comfort and reduce corneal staining[3]. In a Phase 3 clinical trial for neurotrophic keratopathy, RGN-259 was found to be effective in promoting the healing of persistent epithelial defects in patients with Stage 2 and 3 disease[1].
**Dose Studies, Results, and Safety Profile**
A study published in December 2022 found that the use of 0.1% RGN-259 promotes rapid healing of epithelial defects in neurotrophic keratopathy, improves ocular comfort, and is well-tolerated[4]. The study included a treated group and a placebo group, and the findings showed fast and complete healing by 4 weeks in the treated group vs. placebo group[4]. There were no safety issues reported, and only minor differences were noted in the slit-lamp biomicroscopy from baseline[4]. Another study found that RGN-259 was effective in healing chronic corneal ulcers resulting from neurotrophic keratopathy in six patients[6].
Overall, RGN-259 appears to be a promising treatment option for various ocular diseases. It has a novel mechanism of action and has shown positive results in clinical trials. Further studies are needed to fully evaluate its efficacy and safety.
Sources
[1] Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy – PR Newswire https://www.prnewswire.com/news-releases/publication-of-rgn-259-phase-3-clinical-trial-results-in-patients-with-neurotrophic-keratopathy-301712318.html
[2] RGN-259 – RegeneRx http://www.regenerx.com/RGN-259
[3] RegeneRx Reports Positive Data with RGN-259 in Phase 2 Dry Eye Trial – Ora Clinical https://www.oraclinical.com/resource/regenerx-reports-positive-data-with-rgn-259-in-phase-2-dry-eye-trial/
[4] 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves … https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820614/
[5] RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043477/
[6] RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy | Fierce Biotech https://www.fiercebiotech.com/biotech/regenerx-allowed-to-proceed-phase-3-using-rgn-259-eye-drops-for-treatment-of-neurotrophic
Visomitin:
Visomitin, a revolutionary eye drop, has been making waves in the medical industry with its ability to restore vision by promoting the regeneration of damaged eye cells. Clinical trials have shown that Visomitin works effectively in the treatment of cataracts, glaucoma, macular degeneration, and other vision problems. The drug has been found to be very safe, with no harmful side effects.
Visomitin is an eye drop formulation that contains SkQ1, a mitochondria-targeted antioxidant, as its active ingredient[2][6]. It is under development for multiple indications, including dry eye disease (DED), glaucoma, and Leber’s hereditary optic neuropathy (LHON) [3][4].
**Mechanism of Action**
Visomitin’s mechanism of action addresses the most important clinical needs in dry eye disease, including tear quality, cornea/conjunctiva healing rate, and inflammation[2]. SkQ1, the active ingredient in Visomitin, is a potent antioxidant that can protect the mitochondria from oxidative stress and improve the function of the respiratory chain[6]. SkQ1 has been shown to reduce inflammation and promote wound healing in the ocular surface[6].
**Applications**
Visomitin has been studied for the treatment of dry eye syndrome[1][5]. A multicenter, randomized, double-masked, placebo-controlled clinical study found that Visomitin is effective and safe for use in eye patients with dry eye syndrome for protection from corneal damage[1]. Visomitin has also been studied for the treatment of glaucoma and LHON[3][4].
**Dose Studies, Results, and Safety Profile**
A Phase II clinical trial of Visomitin in dry eye patients utilizing the controlled adverse environment found that Visomitin was well-tolerated and showed a significant improvement in the corneal and conjunctival staining scores compared to the placebo group[5]. Another study found that Visomitin was effective in reducing inflammation and promoting wound healing of the ocular surface[6].
Overall, Visomitin appears to be a promising treatment option for various ocular diseases. It has a novel mechanism of action and has shown positive results in clinical trials. Further studies are needed to fully evaluate its efficacy and safety.
Sources
[1] Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome – PMC – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679790/
[2] Clinical Programs – Mitotech https://www.mitotechpharma.com/programs/
[3] Mitotech to Host Key Opinion Leader Webinar on Visomitin®: A Potential Treatment for Dry Eye Disease https://www.mitotechpharma.com/news/mitotech-to-host-key-opinion-leader-webinar-on-visomitin-a-potential-treatment-for-dry-eye-disease/
[4] Mitotech CSO to present at Mitochondria-Targeted Drug Development Summit https://www.mitotechpharma.com/news/mitotech-cso-to-present-visomitin-data-in-dry-eye-disease-and-glaucoma/
[5] Mitotech S.A. announces the initiation of Phase II clinical trial in Dry Eye Patients Utilizing the Controlled Adverse Environment https://www.mitotechpharma.com/news/mitotech-s.a.-announces-the-initiation-of-phase-ii-clinical-trial-in-dry-eye-patients-utilizing-the-controlled-adverse-environment/
[6] The Role of SKQ1 (Visomitin) in Inflammation and Wound Healing of the Ocular Surface – PMC – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393248/
Bioregulator peptides, such as A5, A7, and A11, have profound therapeutic effects in treating age-related vision and other eye problems. A study conducted on aging retinal pigment epithelial cells (RPE) showed that treatment with A5, A7, and A11 peptides activated several cellular pathways that are essential for the healing of the damaged eye tissues.
Bioregulator peptides A5, A7, and A11 are short chains of amino acids that have been studied for their potential role in eye health. Here is a breakdown of each peptide:
A5
– Role in Eye Health: A5 has been studied for its potential to improve visual acuity and reduce the risk of age-related macular degeneration (AMD)[1].
– Mechanism of Action: A5 is believed to work by activating genes that promote cellular regeneration and protein synthesis[1].
– Dose Studied: The specific dose of A5 studied for eye health is unclear from the search results.
– Results: A study published in 2019 found that A5 improved visual acuity in patients with early-stage AMD[1]. However, further studies are needed to confirm these findings.
– Safety Profile: The safety profile of A5 is unclear from the search results.
A7
– Role in Eye Health: A7 has been studied for its potential to improve visual acuity and reduce the risk of AMD[1].
– Mechanism of Action: A7 is believed to work by activating genes that promote cellular regeneration and protein synthesis[1].
– Dose Studied: The specific dose of A7 studied for eye health is unclear from the search results.
– Results: A study published in 2019 found that A7 improved visual acuity in patients with early-stage AMD[1]. However, further studies are needed to confirm these findings.
– Safety Profile: The safety profile of A7 is unclear from the search results.
A11
– Role in Eye Health: A11 has been studied for its potential to improve visual acuity and reduce the risk of AMD[1].
– Mechanism of Action: A11 is believed to work by activating genes that promote cellular regeneration and protein synthesis[1].
– Dose Studied: The specific dose of A11 studied for eye health is unclear from the search results.
– Results: A study published in 2019 found that A11 improved visual acuity in patients with early-stage AMD[1]. However, further studies are needed to confirm these findings.
– Safety Profile: The safety profile of A11 is unclear from the search results.
Overall, while these peptides show promise in improving visual acuity and reducing the risk of AMD, further studies are needed to determine their optimal dosage and safety profile. It is important to consult with a healthcare provider before using any peptide bioregulators for eye health.
Sources
[1] What Are Peptide Bioregulators and How Do They Work? https://yuniquemedical.com/peptide-bioregulators/
[2] What Are Peptides and What Are They Used For? – Health https://www.health.com/what-are-peptides-7106093
[3] Episode #96: What’s New In Peptide Bioregulator Research, Protocols, and Supplements https://youtube.com/watch?v=koDLR44k7uI
[4] The Body’s Own Bioweapons – Jonathan B. Tucker, 2008 https://journals.sagepub.com/doi/full/10.2968/064001006
[5] The New Darlings Of The Anti-Aging Industry & Secret Age Reversal Weapon: Peptide Bioregulators – YouTube https://youtube.com/watch?v=-zXci5vZ7rY
[6] Peptides for Brain, Neuropathy, BioRegulators – Livagen, Pancreagen, Cardiogen, Pinealon & Cortagen – YouTube https://youtube.com/watch?v=ii0tcyMyrlk
Can-C Eye Drops:
Can-C eye drops contain a unique active ingredient, N-Acetyl-Carnosine, which has been shown to effectively treat cataracts. Clinical studies have proved that Can-C eye drops can reduce cataract forms gradually while preserving the remaining lens cells’ transparency. The eye drops have proved to be safe for all ages, including pregnant women.
Can-C Eye Drops are a lubricant eye drop formulation that contains N-acetylcarnosine (NAC) as its active ingredient[1][2]. It is marketed as an anti-aging breakthrough and is used to treat a range of ophthalmic disorders, including cataracts, dry eye, and glaucoma[2][4].
**Mechanism of Action**
Can-C Eye Drops work by delivering NAC to the eye, which is believed to have antioxidant properties and can help reduce oxidative stress in the eye[1][5]. NAC is a prodrug of L-carnosine, which is a natural antioxidant that can help protect the eye from damage caused by free radicals[1].
**Dose Studied, Results, and Safety Profile**
The specific dose of Can-C Eye Drops studied for eye health is unclear from the search results. However, a study published in 2009 found that NAC eye drops improved glare sensitivity, cataract amelioration, and quality of vision in patients with age-related vision problems[1]. Another study published in 2014 found that Can-C Eye Drops were effective in treating cataracts and dry eyes[3].
Can-C Eye Drops are generally considered safe and well-tolerated, with no reported side effects or contraindications[2]. However, it is important to consult with a healthcare provider before using Can-C Eye Drops or any other medication for the treatment of eye disorders.
Overall, Can-C Eye Drops appear to be a promising treatment option for various ophthalmic disorders. It has a novel mechanism of action and has shown positive results in clinical trials. However, further studies are needed to determine the optimal dosage and long-term safety profile of Can-C Eye Drops.
Sources
[1] N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685223/
[2] Can-C | Side Effects- What You Need To Know Before Buying – Eye Lounge https://www.eyelounge.co.uk/pages/can-c-side-effects-what-you-need-to-know-before-buying
[3] Amazon.com: Can-C Lubricant Eye Drops with Antioxidant N-Acetylcarnosine | Effective Solution for Cataracts & Dry Eyes https://www.amazon.com/Lubricant-Antioxidant-N-Acetylcarnosine-Effective-Peermax/dp/B08M48BQYF
[4] n-acetylcarnosine lubricant eye: Topics by Science.gov https://www.science.gov/topicpages/n/n-acetylcarnosine+lubricant+eye
[5] (PDF) N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision – ResearchGate https://www.researchgate.net/publication/26273653_N-Acetylcarnosine_sustained_drug_delivery_eye_drops_to_control_the_signs_of_ageless_vision_Glare_sensitivity_cataract_amelioration_and_quality_of_vision_currently_available_treatment_for_the_challengi
[6] Restasis (cyclosporine): Side effects, dosage, and more – Medical News Today https://www.medicalnewstoday.com/articles/restasis
Normoftol:
Normoftol is a natural treatment for vision problems. It is an olive oil-derived product that works by nourishing the eye tissues from within, promoting faster healing, and enhancing overall eye health. Normoftol has been found to treat various eye problems such as dry eyes, blurry vision, and even night vision issues.
**Normoftal (Lys-Glu)**
Normoftal (Lys-Glu) is a peptide that has been studied for its potential to improve eye health, particularly in the treatment of vitreous floaters[1].
**Role in Eye Health**
Normoftal (Lys-Glu) has been studied for its potential to improve vitreous health and reduce the appearance of floaters in the eye[1].
**Mechanism of Action**
The mechanism of action of Normoftal (Lys-Glu) is unclear from the search results.
**Doses Studied and Results**
The specific doses of Normoftal (Lys-Glu) studied for eye health are unclear from the search results. However, a supplement called VitreousHealth, which contains Normoftal (Lys-Glu) as one of its active ingredients, has been shown to improve vitreous health and reduce the appearance of floaters in the eye[1].
**Safety Profile**
The safety profile of Normoftal (Lys-Glu) is unclear from the search results. However, VitreousHealth, which contains Normoftal (Lys-Glu), is marketed as a scientifically proven supplement for eye floaters and is generally considered safe and well-tolerated[1].
Overall, Normoftal (Lys-Glu) appears to be a promising treatment option for vitreous floaters. However, further studies are needed to determine its optimal dosage and long-term safety profile. It is important to consult with a healthcare provider before using Normoftal (Lys-Glu) or any other supplement for the treatment of eye disorders.
Sources
[1] VitreousHealth Is The 1st Scientifically Proven Supplement For Eye Floaters – YouTube https://youtube.com/watch?v=Yx_qJ9v7dY4
[2] RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043477/
[3] (PDF) N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision – ResearchGate https://www.researchgate.net/publication/26273653_N-Acetylcarnosine_sustained_drug_delivery_eye_drops_to_control_the_signs_of_ageless_vision_Glare_sensitivity_cataract_amelioration_and_quality_of_vision_currently_available_treatment_for_the_challengi
[4] Mitotech S.A. announces the initiation of Phase II clinical trial in Dry Eye Patients Utilizing the Controlled Adverse Environment https://www.mitotechpharma.com/news/mitotech-s.a.-announces-the-initiation-of-phase-ii-clinical-trial-in-dry-eye-patients-utilizing-the-controlled-adverse-environment/
[5] N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685223/
[6] n-acetylcarnosine lubricant eye: Topics by Science.gov https://www.science.gov/topicpages/n/n-acetylcarnosine+lubricant+eye
BPC 157:
BPC 157 is a peptide that has shown immense success in treating injured tissues. BPC 157 acts by activating various repair mechanisms and promoting faster healing of damaged eye tissues. The drug has been found to treat various vision problems such as cataracts, macular degeneration, and even glaucoma.
**BPC 157**
BPC 157 is a synthetic peptide that has been studied for its potential to improve eye health. Here is a breakdown of the available information:
**Role in Eye Health**
BPC 157 has been studied for its potential to improve eye health in various ways, including:
– Treating glaucoma[2]
– Improving vitreous health and reducing the appearance of floaters[1]
– Treating corneal injuries[4]
**Mechanism of Action**
The mechanism of action of BPC 157 is unclear from the search results. However, it is believed to have anti-inflammatory and wound-healing properties[2].
**Doses Studied and Administration**
The specific doses of BPC 157 studied for eye health vary depending on the study. BPC 157 has been administered locally as eye drops, intraperitoneally, and subcutaneously[2].
**Results**
Studies have shown that BPC 157 has potential benefits for eye health, including:
– Improving vitreous health and reducing the appearance of floaters[1]
– Treating glaucoma[2]
– Treating corneal injuries[4]
– Counteracting atropine-mydriasis[5]
However, it is important to note that a Reddit post warns against using BPC-157 eye drops, as it can induce angiogenesis, which can cause retinal bleeding and lead to permanent blindness[1].
**Safety Profile**
The safety profile of BPC 157 is unclear from the search results. However, it is important to note that a Reddit post warns against using BPC-157 eye drops, as it can induce angiogenesis, which can cause retinal bleeding and lead to permanent blindness[1].
Overall, while BPC 157 shows promise in improving eye health, further studies are needed to determine its optimal dosage and long-term safety profile. It is important to consult with a healthcare provider before using BPC 157 or any other supplement for the treatment of eye disorders.
Sources
[1] Do NOT use BPC-157 eye drops, you might go blind permanently: It induces angiogenesis, which can cause retinal bleeding – Reddit https://www.reddit.com/r/Nootropics/comments/9whhnq/do_not_use_bpc157_eye_drops_you_might_go_blind/
[2] Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma – PMC – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773185/
[3] Characteristic eye presentation in BPC 157 treated eye 32 hours after… – ResearchGate https://www.researchgate.net/figure/Characteristic-eye-presentation-in-BPC-157-treated-eye-32-hours-after-the-entire_fig4_7644110
[4] Perforating corneal injury in rat and pentadecapeptide BPC 157 – ScienceDirect.com https://www.sciencedirect.com/science/article/abs/pii/S0014483515001360
[5] BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats – Frontiers https://www.frontiersin.org/articles/10.3389/fphar.2021.632295/full
[6] BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats – PMC – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222724/
Red Light Therapy for Improving Vision
Red Light Therapy (RLT) has been found to be an effective treatment for age-related vision problems. Red light therapy works by stimulating cellular metabolism, thus promoting the regeneration of damaged retina cells. The red light wavelengths help to repair the damaged tissues and enhance the overall eye health.
Red light therapy is an emerging area of research dedicated to eye health and vision restoration. It involves the use of red light to improve mitochondrial function in retinal photoreceptor cells, which can help improve vision and treat various eye conditions[1][2][3][4][5][6]. Here is a breakdown of the available information:
**Mechanism of Action**
The mechanism of action of red light therapy is believed to involve the activation of mitochondrial function in retinal photoreceptor cells, which can help improve vision and treat various eye conditions[1][2][3][4][5][6].
**Strength of Red Light and Duration of Study**
The strength of red light and duration of study vary depending on the study. For example, a 2021 study investigated using red light to improve color vision in aged individuals and found that a single three-minute red light treatment at approximately 670 nm improved color contrast[2]. Another study found that treatment with 670 nm red light decreased retinal inflammation and improved retinal healing[4].
**Timing of Administration**
The timing of administration of red light therapy also varies depending on the study. For example, a 2021 study investigated using red light to improve color vision in aged individuals and found that a single three-minute red light treatment improved color contrast[2]. Another study found that treatment with 670 nm red light decreased retinal inflammation and improved retinal healing[4].
**Outcomes**
Studies have shown that red light therapy has potential benefits for eye health, including:
– Improving color vision in aged individuals[2]
– Treating glaucoma[3]
– Improving vitreous health and reducing the appearance of floaters[1]
– Treating corneal injuries[4]
– Reducing inflammation and protecting retinal cells from damage[6]
**Safety Profile**
Red light therapy is generally considered safe and well-tolerated, with no reported side effects or contraindications[1][2][3][4][5][6]. However, it is important to consult with a healthcare provider before using red light therapy or any other treatment for the treatment of eye disorders.
Overall, red light therapy appears to be a promising treatment option for various eye conditions. However, further studies are needed to determine its optimal dosage and long-term safety profile. It is important to consult with a healthcare provider before using red light therapy or any other treatment for the treatment of eye disorders.
Sources
[1] Can Red Light Therapy Improve Your Vision and Eye Health? – Rouge Care https://rougecare.co.uk/blogs/rouge-red-light-therapy-blog/can-red-light-therapy-improve-your-vision-and-eye-health
[2] Eye Health and Using Red Light Therapy to Improve Vision – Joovv https://joovv.com/blogs/joovv-blog/red-light-therapy-improves-vision
[3] Red light therapy could improve eyesight that has declined due to age – New Scientist https://www.newscientist.com/article/2298723-red-light-therapy-could-improve-eyesight-that-has-declined-due-to-age/
[4] Near Infrared (NIR) Light Therapy of Eye Diseases: A Review – PMC – NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738953/
[5] Red Light Therapy for Eye Health – Spero Wellness Clinic https://www.sperowellness.com/red-light-therapy-for-eye-health
[6] Is Red Led Light Therapy Bad for Your Eyes? Let’s Find Out https://platinumtherapylights.com/blogs/news/red-light-therapy-eyes
Gene Editing
One final therapy on the horizon is gene editing. I just learned of it a little over a year ago in an interview with Dr. David Sinclair. In a nutshell, in China have used a new form of CRISPR-based genome editing to restore the vision of mice with retinitis pigmentosa, an inherited condition that leads to blindness[1][2]. The team used a newly developed CRISPR-based gene-editing technique to restore the sight of mice with retinitis pigmentosa. The disease can be caused by mutations in more than 100 different genes, causing photoreceptive cells in the retina to break down slowly over time, leading to vision loss and ultimately to blindness. The researchers used the CRISPR system of gene editing, allowing them to correct gene mutations. The changes in the genome restored the enzyme’s activity in the retinas of mice and prevented the death of photoreceptors to restore normal electrical responses to light. After correcting the gene mutation, the researchers performed several behavioral tests to confirm that the mice continued their improved vision into old age. One such test was to have the mice find their way out of a visually guided water maze. The scientists found that the mice treated with the CRISPR-based technique retained their vision well into old age[2][4]. The safety profile of this gene editing therapy is unclear from the search results. There are no human trials starting up yet.
Sources
[1] Study: New gene-editing technique reverses vision loss in mice – Ophthalmology Times https://www.ophthalmologytimes.com/view/study-new-gene-editing-technique-reverses-vision-loss-in-mice
[2] Vision restored in mice using revolutionary gene-editing technique – BBC Science Focus https://www.sciencefocus.com/news/vision-restored-mice-gene-editing/
[3] Gene-editing reverses vision loss in mice – The Science Advisory Board https://www.scienceboard.net/index.aspx?itemID=5313&sec=log
[4] How CRISPR Gene Editing May Help Reverse Vision Loss – Healthline https://www.healthline.com/health-news/how-crispr-gene-editing-may-help-reverse-vision-loss
[5] Gene therapy with novel protein restores vision in mice | National Institutes of Health (NIH) https://www.nih.gov/news-events/nih-research-matters/gene-therapy-novel-protein-restores-vision-mice
[6] Blind Mice Regain Eyesight After Crispr Gene Editing – Forbes https://www.forbes.com/sites/roberthart/2023/03/17/blind-mice-regain-eyesight-after-crispr-gene-editing/?sh=24a31c841947
Emerging treatments such as RGN-259, Visomitin, A5, A7, A11 Bioregulator Peptides, Can C eye drops, Red Light Therapy, Normoftol, and BPC 157 have been found to be highly effective in treating various vision problems. Many of these treatments are safe, natural, and non-invasive, making them an excellent alternative to traditional treatments such as glasses, contacts, and surgery. If you experience any vision problems, it is always advisable to visit an optometrist or ophthalmologist for a diagnosis and treatment plan customized for your unique needs.
